Search results
Richard A. Gonzalez is Chairman of the Board and Chief Executive Officer of AbbVie, a… · Experience: AbbVie · Location: North Chicago · 500+ connections on LinkedIn.
- 500+
- Abbvie
- 37K
Learn about Richard A. Gonzalez, the Chairman of the Board and Chief Executive Officer of AbbVie, a global biopharmaceutical company. He is also the founding CEO of AbbVie, a spin-off from Abbott, and a long-time leader in the Chicago community.
Feb 20, 2024 · AbbVie CEO Richard Gonzalez, the only chief executive in the big drugmaker’s history, will retire on July 1, the company said Tuesday. Gonzalez will be succeeded by current company president and Chief Operating Officer Robert Michael.
Feb 20, 2024 · Mr. Gonzalez, who has served as CEO since the company's formation in 2013, will retire from the role of CEO and become executive chairman of the board of directors, effective July 1, 2024. Additionally, the board has appointed Mr. Michael as a member of the board of directors effective July 1, 2024. "On behalf of AbbVie's board, I am extremely ...
May 7, 2024 · Our culture of innovation and responsibility starts with our board of directors and extends out to every member of the company. Our board members work closely with AbbVie leaders to maintain our focus of putting patients first. Richard A. Gonzalez. Chairman of the Board and Chief Executive Officer. AbbVie Inc.
Richard Gonzalez is the chairman of the board and CEO of pharmaceutical company AbbVie. Originally an executive vice president at Abbott Laboratories, he was asked to lead...
People also ask
How much does Richard Gonzalez make at AbbVie?
What happened to AbbVie CEO Richard Gonzalez?
Who is AbbVie's new CEO?
Who is Richard Gonzalez?
Will Gonzalez leave a new chapter for Abbvie after the Humira era?
Who owns Allergan & AbbVie?
Feb 22, 2024 · Gonzalez led AbbVie to become one of the most successful pharmas in the world with Humira and Allergan deals, but also faced criticism for patents and pricing. Read how he grew AbbVie's pipeline, market valuation and R&D spending.